Clinical trials: Menopausal Vasomotor Symptoms
Menopause, Hot Flashes
Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)
This study will evaluate whether an 8-week course of a standardized herbal extract containing Shatavari and natural bio-enhancer ingredients can reduce menopausal symptoms in post-menopausal women.
- Trial name
- RENEW (NCT07834463)
- Testing
- Shatavari (Asparagus racemosus) Extract
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- India Glycols Ltd
Hot Flushes, Menopause, Postmenopause
Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes
This is a research study to evaluate the effectiveness, safety and side effects of several dose levels of esterified estrogens (EE) and methyltestosterone (MT) given individually and in combination compared to a placebo (a tablet…
- Trial name
- NCT00160342
- Testing
- Esterified Estrogens (EE) and Methyltestosterone (MT)
- Where
- 125 sites in United States, Canada and 1 more
- Volunteers
- 1,251 people
- Sponsor
- Solvay Pharmaceuticals
Vasomotor Symptoms
Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause
The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of moderate to severe vasomotor symptoms associated with…
- Trial name
- NCT00421031
- Testing
- DVS-233 SR
- Where
- 41 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy, Menopause
One Week Clinical Study in Subjects With Menopausal Symptoms
The goal of this clinical trial is to Examine the Benefits of an Oral Product in Subjects With Menopausal Symptoms. The main questions it aims to answer are: 1.
- Trial name
- NCT06794021
- Testing
- Dietary Supplement with Proprietary Herbal Extract Blend and GABA
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Olly, PBC
Menopausal Symptoms
Randomized Placebo Controlled Clinical Study of an Oral Product in Subjects With Menopausal Symptoms
The objective of this study is to assess the safety and effectiveness of a dietary supplement for symptom relief in subjects with menopausal symptoms over the course of five weeks of continuous daily use.
- Trial name
- NCT06787443
- Testing
- Dietary Supplement with Proprietary Herbal Extract Blend and GABA
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Olly, PBC
Vasomotor Symptoms (VMS)
Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)
The purpose of this study is to determine the effective dose or dose range of AR08 in the treatment of VMS in menopausal females.
- Trial name
- NCT02049164
- Testing
- AR08
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Vasomotor Symptoms (VMS) Associated With Menopause
An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies
This is an observational study to learn more about vasomotor symptoms (VSM) burden and treatment patterns in menopausal women before and after participating in OASIS studies.
- Trial name
- OASIS STAR (NCT06949553)
- Testing
- No study intervention
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Hot Flashes
A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes
This is a randomized, double-blind study to compare the efficacy and safety of daily doses of Cenestin 0.3 mg tablets to placebo in reducing the frequency and severity of moderate to severe hot flashes in postmenopausal women.
- Trial name
- NCT00272935
- Testing
- Cenestin 0.3 mg Tablets
- Where
- 49 sites in United States
- Volunteers
- 400 people
- Sponsor
- Duramed Research
Menopause, Vasomotor; Syndrome
Efficacy of Nano-Pso Therapy in Menopause
Vasomotor syndrome is prevalent in 85% of postmenopausal women, hormone therapy in menopause is first-line therapy, but 38% of patients have some contraindication for its use.
- Trial name
- NCT06432816
- Testing
- NANO-PSO
- Where
- Mexico
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Distribuidora Biolife SA de CV
Postmenopausal Symptoms
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
The purpose of this study is to assess the safety \& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.
- Trial name
- N30-003 (NCT01361308)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- 74 sites in United States
- Volunteers
- 614 people
- Sponsor
- Noven Therapeutics
Menopause, Hot Flashes
A Double-Blind Study to Evaluate the Effect of Femarelle® on Menopausal on Vasomotor Symptoms
The purpose of this study is to test the effects of Femarelle ( a plan-derived SERM) on hot flushes and quality of life in menopausal women.
- Trial name
- NCT01063725
- Testing
- Femarelle
- Where
- 5 sites in Israel
- Volunteers
- 200 people
- Sponsor
- Se-cure Pharmaceuticals Ltd.
Perimenopause, Perimenopausal Depression
A Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women
The goal of this observational study is to investigate the accuracy of the device in characterizing perimenopausal and menopausal symptoms including vasomotor symptoms, anxiety, sleep quality compared to self-reported symptoms…
- Conditions
- Perimenopause, Perimenopausal Depression, Perimenopausal Insomnia, Perimenopausal Women
- Trial name
- NCT07022925
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- IdentifyHer Limited
Postmenopause
Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.
The purpose of this study is to evaluate vasomotor symptoms (VMS) control of the continuous regimen 17 b estradiol/trimegestone combination.
- Trial name
- NCT00195455
- Testing
- Trimegestone, 17b Estradiol
- Where
- 6 sites in Mexico
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hot Flashes
A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Skylight 4 (NCT04003389)
- Testing
- fezolinetant
- Where
- 182 sites in United States, Canada and 6 more
- Volunteers
- 1,831 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vasomotor Symptoms, Hot Flushes
Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women
The purpose of this Phase III trial is to evaluate the efficacy of oral administration of dehydroepiandrosterone (DHEA) combined with acolbifene (a selective estrogen receptor modulator (SERM)) on vasomotor symptoms (hot flushes)…
- Trial name
- NCT01452373
- Testing
- DHEA and Acolbifene
- Where
- 15 sites in Canada
- Volunteers
- 238 people
- Sponsor
- EndoCeutics Inc.
Postmenopausal Women With Moderate Vasomotor Symptoms
Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause
The purpose of this study is to evaluate the efficacy of FITOGYN vs. placebo on the vasomotor symptomatology associated with menopause, to evaluate the symptoms of anxiety, the metabolic parameters in menopause and to evaluate…
- Trial name
- TRYSEM (NCT01116310)
- Testing
- Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)
- Where
- 20 sites in Spain
- Volunteers
- 166 people
- Sponsor
- Laboratorios Casen-Fleet S.L.U.
Vasomotor Symptoms Associated With Menopause, Healthy Volunteers
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneous (SC) injection to healthy men and to postmenopausal women with or without any vasomotor symptoms (VMS) or…
- Trial name
- NCT07118891
- Testing
- ABCL635
- Where
- 13 sites in Canada
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- AbCellera Biologics Inc.
Hot Flashes, Hot Flash
Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women
The goal of this study is to evaluate the efficacy of a neurokinin 1,3 antagonist on improving vasomotor symptoms (VMS) and overall menopause symptoms in women between the ages of 40-70.
- Conditions
- Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats
- Trial name
- NCT07408115
- Testing
- JDS-HF3.0
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Bonafide Health
Hot Flashes
Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of Gabapentin that is being studied for the treatment of Hot Flashes/Hot Flushes in postmenopausal women
- Trial name
- Breeze3 (NCT01080300)
- Testing
- Gabapentin Extended Release
- Where
- 66 sites in United States
- Volunteers
- 600 people
- Sponsor
- Depomed